Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Michael L. Beshiri(National Cancer Institute), Kathleen Kelly(The Ohio State University), Eva Corey(University of Washington), Keith H. Jansson(National Cancer Institute), William L. Dahut(National Cancer Institute), Caitlin M. Tice(National Cancer Institute), Adam G. Sowalsky(National Cancer Institute), Kerry M. McGowen(National Cancer Institute), Fatima Karzai(National Institutes of Health), Supreet Agarwal(University of Iowa), Aian Neil Alilin(National Cancer Institute), Qi Yang, Holly M. Nguyen(University of Washington), JuanJuan Yin(National Cancer Institute), Crystal Tran(National Cancer Institute)
Cited by 0
Related Papers
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
|Cell|1983|2.3k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314